Fig. 2

NK cell proportion (A), IFN-γ producing NK cell proportion (B), CD56^bright NK cell proportion (C), and ratio of CD56^bright NK cell and CD56^dim NK cell (D) according to the BCLC stage. NK, natural killer; IFN, interferon; BCLC, Barcelona clinic liver cancer; BCLC 0, patients with BCLC stage 0; BCLC A, patients with BCLC stage A; and BCLC BCD, patients with BCLC stage B, C, or D